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Summary The present paper describes two immunoconjugates consisting of an anti-epidermal growth factor receptor (EGFR) monoclonal
antibody (MAb), named Mint5, covalently linked to the type 1 ribosome-inactivating proteins (RlPs) ocymoidine (Ocy) and pyramidatine (Pyra)
from Saponaria ocymoides and Vaccaria pyramidata respectively. Both antibody and toxins are shown to retain their respective biological
properties upon chemical conjugation. The immunoconjugates exert specific inhibition of EGFR expressing target cell proliferation and protein
synthesis in in vitro assays and also inhibit the growth of grafted human tumour cells in nude mice.
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The clinical use of immunotoxins for the treatment of cancer is
currently under evaluation worldwide. The therapeutic potentiality
of immunotoxins and preclinical and clinical results over the last
20 years have been reviewed recently (Thrush et al, 1996), indi-
cating that, although immunotoxins seem promising for systemic
therapy of haematological malignancies, a number of different
problems still need to be solved, especially for the treatment of
solid tumours. In particular, the refining of dose regimen and
administration route, the combination with chemotherapy and the
reduction of immunogenicity are the major goals of future
research. In this paper, we describe the preparation of two new
immunoconjugates made of an anti-epidermal growth factor
receptor monoclonal antibody, named MintS, chemically linked to
either ocymoidine or pyramidatine, toxins from Saponaria
ocymoides and Vaccariapyramidata respectively.
The epidermal growth factor (EGF) and its receptor play a crit-
ical role in the growth and regulation of many normal and malig-
nant cell types. EGFR overexpression is a common feature in most
carcinomas and correlates with poor prognosis (Fox et al, 1994).
The potential value of EGFR as a target for the diagnosis and
therapy of human tumours has been recognized for several years,
and the use of anti-EGFR monoclonal antibodies may provide
therapeutic tools in the treatment of tumours overexpressing the
receptor (Ennis et al, 1991).
Moreover, immunoconjugates of EGFR-specific monoclonal
antibodies to either gelonin (Ozawa et al, 1989) or ricin A chain
(Masui et al, 1989) were shown to reduce the growth of human
tumour cells transplanted into athymic mice.
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Mint5 is a murine monoclonal antibody raised against the
human epidermoid carcinoma-derived cell line, A431. It recog-
nizes an epitope associated with the ligand-binding site of EGFR
and induces receptor internalization. Mint5 blocks EGF-induced
EGFR tyrosine kinase activation in A431 cells and inhibits both in
vitro and in vivo tumour growth. These characteristics suggest that
MintS might be a valuable candidate for the treatment of EGFR-
overexpressing tumours (Tosi et al, 1995). In order to improve the
cytolytic activity of MintS, two immunotoxins were prepared by
linking MintS to the two recently described RIPs, ocymoidine and
pyramidatine, from Saponaria ocymoides and Vaccaria pyrami-
data respectively (Bolognesi et al, 1995). Ocymoidine and pyra-
midatine purified proteins run as a single band on polyacrylamide
gel electrophoresis at relative molecular weights of about 30.2
and 28.0 kDa respectively. They show a basic pl around 9.5. The
two proteins have the characteristics of the ribosome-inactivating
proteins isolated from several plants belonging to the Caryo-
phyllaceae family.
Many plant tissues contain proteins that specifically inhibit
protein synthesis by inactivating eukaryotic ribosomes (Barbieri et
al, 1993). Most ribosome-inactivating proteins occur as mono-
meric proteins (type 1 RIPs) of molecular mass around 30 kDa,
exhibit strong alkaline isoelectric points, sometimes exceeding 10
and may beN-glycosylated. In some cases RIP A chain is part ofa
heterodimeric protein (type 2 RIPs) in whichit isjoined to a galac-
tose-binding lectin (B chain) by a single disulphide bond. Ricin
and abrin are examples of such heterodimers and are among the
most cytotoxic compounds known. RIPs from plants share the
common property of inactivating ribosomes, hence inhibiting
protein synthesis. This is owing to their highly specific RNA N-
glycosidase activity that cleaves the glycosidic bond ofadenine4324
in rat liver28S rRNA (Endo et al, 1988). This site ofaction is adja-
cent to the a-sarcin site ofaction (RIP fromAspergillus giganteus)
and is contained in the exposed loop termed a-sarcin domain. The
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latter toxin cleaves the phosphodiester bond between guanine4325
and adenine4326 in rat 28S rRNA, which also results in loss ofribo-
some function (Endo et al, 1983).
MATERIALS AND METHODS
Preparation of immunoconjugates
MintS MAb was purified by two ion exchange chromatography
runs from conditioned serum-free media obtained by cultivation of
hybridoma cells (kindly provided by Dr Colnaghi MI INT Milan)
in a hollow fibre bioreactor (Acusyst R, Endotronics).
Pyramidatine and ocymoidine were purified from the seeds of
Saponaria ocymoides and Vaccaria pyramidata, respectively, by a
modification of a previously described method (Bolognesi et al,
1990), including sequential ion-exchange chromatography on S-
Sepharose and CM-Sepharose columns (Pharmacia, Sweden),
followed by hydrophobic interaction chromatography on aphenyl-
Sepharose column (Pharmacia) for Saponaria ocymoides protein,
or by filtration on Amicon PM1O membrane for Vaccaria pyrami-
data protein (Bolognesi et al, 1995).
Immunoconjugates were prepared essentially according to a
previously described method (Thorpe et al, 1988), based on the use
of2-iminothiolane (2-IT).
In particular, activation of pyramidatine or ocymoidine was
performed by dissolving RIP to a concentration ofabout 3 mg ml-'
in 50 mm sodium borate buffer, pH 9.0. RIP labelled with 1251 (for
a total of 106 c.p.m.) was added to this solution. After centrifuga-
tion to remove corpuscular material, 2-IT, dissolved immediately
before use in 50 mm sodium borate buffer, pH 9.0, was added at
1-2 mm final concentration. After 60 min at 28°C, solid glycine
was added to the final concentration of 200 mm, and after 15 min,
the Ellman's reagent, dissolved in 50 pl of dimethylformamide
immediately before use, was added to the final concentration of
2.5 mm. After a 15-min incubation at 28°C, the sample was loaded
on a Sephadex G25 Coarse column (25 x 1.6 cm).
The protein peak was eluted in phosphate-buffered Saline (PBS:
0.14 M sodium chloride, 5 mm sodium phosphate buffer, pH 7.15),
collected and the derivatization ratio was determined on a small
amount of sample diluted 1:5 with PBS, by measuring the
absorbances at 280 nm and 412 nm before and after addition of
1/10 (v/v) of a freshly prepared solution of 0.22 M 2-mercap-
toethanol. The MintS monoclonal antibody at a concentration of
1-6 mg ml-' was reacted with 0.3 mM 2-IT, following the proce-
dure described above.
The RIPs were concentrated under nitrogen using an Amicon
concentrator and reduced by adding 1/10 in volume of 0.22 M 2-
mercaptoethanol. The reduced toxins were loaded on a Sephadex
G25 Coarse column (25 x 1.6 cm). The protein peak was collected
in the concentrator containing the derivatized antibody. The reac-
tion mixture was concentrated four times under nitrogen, with a
total incubation time of20 h at room temperature. The mixture was
then loaded on a PBS-equilibrated Sephacryl S-200 HR column
(96 x 2.2 cm) and the same buffer was used as eluent. By
comparing the radioactivity elution profile with the profile of the
absorbance at 280 nm, the various components ofthe mixture were
identified. The RIP-antibody ratio in the pooled fractions
containing the immunoconjugates was calculated by measuring
the absorbance at 280 nm and the radioactivity ofconjugate and of
non-reacted RIPs.
The concentration ofMint-Ocy and Mint-Pyra was determined
by amino acids analysis performed on Amino Quant 1090
(Hewlett Packard) according to the manufacturer's instructions.
Binding of immunoconjugates to target cells
A431 cells (overexpressing EGFR) were fixed to 96-well
microtitre plates. Subsequently, the plates were saturated with Tris-
buffer saline (TBS: 25 mm Tris, pH 7.4, 150 mm sodium chloride),
0.5% Hammarsten casein (Merck Ltd.) and 0.1% Triton X-100.
Serial dilutions ofMint-Ocy and Mint-Pyra immunoconjugates in
TBS, 0.5% Hammarsten casein were added to the plates for 4 h at
37°C. After washings, the binding of immunoconjugates was
demonstrated with a polyclonal rabbit anti-dianthin 32 antiserum
(Strocchi et al, 1992) (1:100 dilution, 4 h at 37°C), which cross-
reacts with ocymoidine and pyramidatine, followed by a 1251-
labelled goat anti-rabbit IgG antiserum (105 c.p.m. per well, 4 h
at 37°C). Bound c.p.m. were measured by a gamma-counter
(Canberra Packard, USA) and background values obtained with
unconjugated Mint5 were subtracted. All experiments were
performed in triplicate.
RNA fragmentation assay
The RNA fragmentation assay was performed as described previ-
ously (Endo and Tsurugi, 1987). Briefly, 35 gl of rabbit reticulo-
cyte lysate (Promega C, Madison, WI, USA) were incubated in the
presence of immunoconjugates at a concentration referred to as
RIPs of6 ,u g ml-' for 20 min at 37°C. The reaction was stopped by
the addition of sodium dodecyl sulphate (SDS) to 0.5% final
concentration. RNA was extracted with phenol, precipitated with
2.5 volumes of ethanol at -20°C for 1 h and resuspended in 20 pl
of 1 M aniline acetate, pH. 4.5. After 30 min incubation on ice,
RNA was extracted twice with ether and ethanol precipitated.
Samples were resuspended in Tris borate EDTA buffer (TBE: 90
mM Tris/HCI, 90 mm boric acid, 3 mm EDTA, pH 8.0), 7 M urea,
0.1% bromophenol blue and 0.1% xylene cyanol. Electrophoresis
was performed on 5% acrylamide gel containing 7 M urea and
TBE, and staining was done with ethidium bromide as described
previously (Stirpe et al, 1988).
Inhibition of protein synthesis in rabbit reticulocyte
lysate
The activity oftoxins, both unconjugated and conjugated to MintS,
was determined measuring the inhibition of protein synthesis by
[35S]methionine (specific activity 100 Ci mmol- , Amersham
Intenational, UK) incorporation in a rabbit reticulocyte lysate
system (Promega C, Madison, WI, USA). The standard reaction
was performed in a 50 g1 final volume containing 35 pl of rabbit
reticulocyte lysate, 40 U RNAasin, 1 mm amino acid mixture
minus methionine, 4 gl of [35S]methionine (40 ,uCi), 0.5 ,ug of
Brome mosaic virus (BMV) RNA and different concentrations of
toxin or immunoconjugate. The mixture was incubated at 37°C for
30 min, then trichloroacetic acid (TCA) precipitation was accom-
plished according to Promega instructions and the amount of
incorporated [35S]methionine was determined by a liquid scintilla-
tion :-counter (Canberra Packard). The amount of the tested
product giving 50% inhibition (IC,0) was calculated.
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Figure 1 Binding of immunoconjugates on A431 target cells. A431 cells,
fixed on microtitre plates, were incubated with serial dilutions of
immunoconjugates. Binding was revealed by a polyclonal rabbit anti-dianthin
32 followed by a 1251-labelled goat anti-rabbit IgG antiserum. Bound c.p.m. are
the mean values of triplicates. Background values obtained with
unconjugated Mint5 were subtracted. Bars denote the standard deviations
from the mean
Inhibition of cell proliferation and protein synthesis on
target cells
Human A431 (human epidermoid carcinoma), MCF7 and SKBR-3
(human breast adenocarcinoma) and Jurkat (EGFR-negative
leukaemia) cell lines were obtained from ATCC (Bethesda, MD,
USA), IGR-OV1 (human ovarian carcinoma) cells were kindly
provided by Dr J Benard (Laboratoire de Pharmacologie
Moleculaire, Institut Gustave Roussy, Villejuif, France). All cell
lines were routinely maintained in RPMI-1640 medium supple-
mented with 10% heat-inactivated fetal calf serum (FCS) and
150 mm glutamine, in a humidified atmosphere of 5% carbon
dioxide at 37°C.
Cell proliferation inhibition assays were performed in 96-well
culture plates. Approximately 5 x 103 cells plated at0.1 ml per well
were incubated with 0.1 ml ofeither MAb, toxin or immunoconju-
gate sample at increasing molarities. After a 48-h incubation at
37°C, and an additional 6-h incubation in the presence of 0.5 ,u Ci
of [3H]thymidine per well, cells were harvested and the [3H]thymi-
dine incorporated determined by liquid scintillation counting in a
beta-plate 1205 counter (Wallac-OY-20101, Turku 10, Finland).
All experimental points were performed in quadruplicate.
As an alternative, 5 x 103 cells, plated at 0.1 ml per well, were
incubated for 1 h at 4°C with 0.1 ml of different samples. Cells
were then incubated for 2 h at 37°C to allow adherence. The plates
were washed twice and 0.2 ml offresh medium was added. After a
48-h incubation at 37°C, with an additional 6-h incubation in the
presence of0.5 ,u Ci of [3H]thymidine per well, radioactivity incor-
poration was measured as described above.
Inhibition of cell protein synthesis was evaluated on target
human cell lines by measuring incorporation of [3H]leucine. The
protocols used were the same as those for the inhibition of cell
proliferation except that the cells were incubated with samples
for 48 h and then 1 ,uCi of [3H]leucine was added to each well.
After an additional 24 h, cells were harvested and the radioactivity
was measured by liquid scintillation counting in a 5-counter
(Canberra Packard). All experimental points were performed in
quadruplicate.
Figure 2 Gel electrophoresis of rRNA from rabbit reticulocyte lysate treated
with immunotoxins. Lane 1, RNA markers (Boehringer Mannheim); lane 2,
Mint-Pyra; lane 3, Mint-Ocy; lane 4, ricin A chain. RIPs were used at a
concentration of 6 ug ml-'. Samples in lanes designated + and - were
respectively treated and not treated with aniline. The arrow indicates the
fragment obtained from RIP-treated ribosomes in the presence of aniline.
Electrophoresis was performed on a 5% acrylamide, 7 M urea gel
Inhibition of growth of transplanted A431 cells in nude
mice
Animal experiments were performed according to UKCCCR
guidelines for the welfare of animals in experimental neoplasia
(Workman et al, 1988).
Four-week-old nu/nu Balb/c mice were purchased from Nossan
(Milan, Italy) and were injected subcutaneously with 107 A431
cells. Mice were divided into four treatment groups, each group
consisting of 24 animals. Immediately after A431 grafting, the
animals were injected intravenously (i.v.) with either 0.525 mg
kg-1 Mint-Ocy or 0.1 mg kg-1 Mint-Pyra. Additional drug admin-
istrations were given i.v. every other day for 9 days (five adminis-
trations) and the total dose was 2.625 mg kg-' for Mint-Ocy and
0.5 mg kg-' forMint-Pyra. Control groups oftumour-bearing mice
were treated similarly with either MintS unconjugated antibody at
1.0 mg kg-' or PBS.
After 12 days of treatment, mice were sacrificed and weighed.
Tumours were removed and weighed separately.
RESULTS
Binding of immunoconjugates to target cells, RNA
fragmentation assay and inhibition of protein synthesis
in a rabbit reticulocyte lysate
Anti EGFR MintS MAb was covalently linked to ocymoidine or
pyramidatine toxin. The RIP-antibody ratio in the conjugates
ranged between 1.76 and 1.98. In order to check the antibody and
toxin functional features, upon chemical conjugation, the immuno-
conjugates were analysed for both antibody binding to relevant
and irrelevant target cells and N-glycosidase activity of toxins by
rRNA fragmentation and cell-free protein synthesis inhibition
assays.
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Figure 3 Inhibitory activity on cell-free protein synthesis. The results are
expressed as the mean of duplicate determinations of [35S]methionine
incorporation as a percentage of untreated controls. Unconjugated Mint5
was found to induce no significant effects on protein synthesis (data not
shown)
Figure 1 shows that Mint5 retains its binding property after
chemical conjugation to ocymoidine or pyramidatine toxins. The
specificity ofthe binding is confirmed by its absence in irrelevant
target cells (data not shown).
The ribosome-inactivating property ofocymoidine and pyrami-
datine was double checked after chemical conjugation oftoxins to
Mint5 by both qualitative RNA fragmentation and quantitative
protein synthesis inhibition tests.
Figure 2 shows the electrophoretic analysis of rRNA from
rabbit reticulocyte lysate after incubation with Mint5 immunocon-
jugates or with ricin. The arrow indicates the RNA fragments that
are obtained by aniline treatment (+) following rRNA incubation
with Mint-Pyra (lane 2), Mint-Ocy (lane 3), as well as ricin A
chain (lane 4). The absence of fragments in samples not treated
with aniline (-) confirms the RNA N-glycosidic activity oftoxins.
Purified ocymoidine and pyramidatine either unconjugated or
chemically linked to Mint5 MAb were analysed for their property
of inhibiting cell-free protein synthesis by a rabbit reticulocyte
lysate system. Results shown in Figure 3 indicate that unconju-
gated pyramidatine and ocymoidine inhibit 50% of protein
synthesis at a concentration of3.6 and 4.8 ng ml-' respectively (1.5
x 10-10 M and 1.58 x 10-10 M), and that this activity is partially
reduced by chemical conjugation to Mint5, being 13.9 and 13.2 ng
ml-' respectively (5.6 x 10-10 M and 4.0 x 10-10 M, referred to RIP).
Unconjugated Mint5 alone does not affect protein synthesis (data
Figure 4 Experimental protocols for (A) inhibition of proliferation, (B)
inhibition of protein synthesis. TOX, toxins; IT, immunotoxins; MAb,
monoclonal antibody
not shown). All functional data taken together indicate that the
specific ribosome-inactivating properties of pyramidatine and
ocymoidine are substantially preserved in the immunoconjugates.
Inhibition of cell proliferation and protein synthesis on
target cells in vitro
The inhibition of cell proliferation and protein synthesis on A431
target cells was performed in vitro following two different proce-
dures reported as protocols 1 and 2 (Figure 4 A and B). In protocol
1, either toxin, immunotoxin or MAb was added at the time of
cell seeding and stayed until the end of the culture, whereas in
protocol 2, samples were removed after 1 h of incubation at 4°C
followed by 2 h ofincubation at 37'C. Figure 5 A shows the effect
on A431 cell proliferation of either unconjugated toxin, Mint5 or
Table 1 In vitro toxicity of Mint-Ocy and Mint-Pyra on different cell lines
Cell proliferation Protein synthesis
(iCso) (iCso)
Cell line EGFR no. per cell Mint-Ocy Mint-Pyra Mint-Ocy Mint-Pyra
A431 2 x 106 5 pM 1.5 pM 10 pM 10 pM
SKBR-3 9 x 104 5 pM 12 pM 55 pM 15 pM
IGR-OV-1 4 x 104 10 pM 7.5 pM 15 pM 5 pM
MCF7 4x 104 3 nM 1 nM 1 nM 8 nM
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Protocol 1
Cell seeding | |[311thymidine
+TOX/IT/MAb 0.5gCiper well
48 h 37 OC 6 h 37 °C
Protocol 2
Cell seeding Washing | [H]thymidine
[ h4°C 0h5° 48[3 per well
- ol - -f g
1 h40C 2h370C 48h370C 6h37 OC
I
B
Protocol 1
Cell seeding F[31-]leucine
+ TOX/lT/MAb 1 1 Ci per well
-
48h37°C 24h37°C
Protocol 2
Cell seeding Washing [711 eucine |
1Oy
M C per well
1 h4°C 2h370C 48h370C 24h37°C
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Figure 5 Inhibition of cell proliferation and protein synthesis on A431 cell line. The results are expressed as the inhibition percentage of cell proliferation or
protein synthesis referred to untreated controls. Each point represents the mean and standard deviation (bars) of quadruplicate determinations of [3H]thymidine
(A and B) or [3H]leucine (C and D) incorporation
immunoconjugate according to protocol 1, indicating that the IC50
of Mint-Ocy and Mint-Pyra immunoconjugates are 6.9 x 10-12 M
and 1.8 x 10-12 M respectively. The immunoconjugates show lower
activities if removed after initial incubation, as in protocol 2, with
IC50 of 3 x 10-" M and 2.9 x 10-" M (Figure 5B). The inhibitory
activities ofunconjugated RIPs are also lower in protocol 2 experi-
ments compared with protocol 1. In fact, IC50 for both ocymoidine
and pyramidatine are >10-8 in protocol 2 and 6-9.6 x 10-'0 in
protocol 1. These proliferation experiments indicate that the
inhibitory activity ofunconjugated Mint5, already reported by Tosi
et al (1995) can be strongly potentiated when conjugated to RIP.
Figure 5C shows that Mint-Ocy and Mint-Pyra added to the
cell culture according to protocol inhibit A431 protein synthesis
with an IC50 of 10-" M, whereas, when added according to protocol
2, IC50 values of 10-11 M and 1.3 x 10-" M, respectively, were
obtained (Figure 5D). Analogously to the inhibition of cell prolif-
eration, protein synthesis inhibition given by unconjugated
ocymoidine and pyramidatine was lower in protocol 2 experiments
with IC50 of2 x 10- M compared with protocol 1 values ofIC50 2 x
10-8 M and 1.5 x 10-8 M respectively. The results from the above in
vitro experiments suggest a different kinetic ofaction for immuno-
toxins on inhibiting proliferation or protein synthesis. In fact,
maximal inhibition of proliferation requires the presence of
immunoconjugate throughout the time of cell culture, whereas
maximal inhibition ofprotein synthesis is reached after only 3 h of
exposure at the beginning of the culture. In order to investigate
Mint-Ocy and Mint-Pyra toxic activity as a function of different
levels of EGFR expression, both proliferation and protein
synthesis experiments were performed on A431, MCF7, SKBR-3
and IGR-OV- 1 cell lines according to protocol 1 ofFigure 4.
Table I shows the concentration ofimmunoconjugates inducing
50% inhibition of cell proliferation or protein synthesis on the
different cell lines. These data indicate the absence of correlation
between the toxic action of immunoconjugates and the number of
EGFRs on the different cells. The specificity of immunotoxins for
EGFR-expressing cells was confirmed on a Jurkat (EGFR-) cell
line in which the toxic effect of the immunoconjugates was not
greater than that ofunconjugated toxins (data not shown).
In vivo experiments
The anti-tumour efficacy of Mint5 immunotoxins was studied by
grafting A431 human tumour cells in athymic mice. The doses of
immunoconjugates injected were based on the previously deter-
mined doses ofocymoidine and pyramidatine killing 50% of mice
(LD50) resulting in 13.5 mg kg-' and 2.57 mg kg-' respectively.
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Table 2 Tumour growth inhibition in athymic mice
Mean body Mean body Mean tumour
weight before weight at end of weight at end of Tumour - body Percentage of
Drug treatment treatment treatment weight ratio inhibition
(g + s.d.) (g ± s.d.) (g ± s.d.)
PBS 17.1 (+2.1) 17.6 (2.8) 0.7(0.3) 0.0397 0
Mint5 16.71(±1.8) 19.5 (±2.8) 0.73 (±0.26) 0.0374 7
Mint-Ocy 16.61 0.9) 15.4 (± 1.6) 0.26 (± 0.13) 0.0168 57
Mint-Pyra 17.33 (±1.6) 16.4 (±1.5) 0.34 (±0.34) 0.021 47
Body and tumour weights were determined individually during treatment and the medium was calculated from the 24 animals of each group. Standard
deviations (s.d.) are indicated in parentheses. The anti-tumour efficacy was estimated by the tumour-body weight ratio at last day of administration. A significant
difference (P < 0.01) was found between the control groups (PBS and Mint5-treated) and the test groups (Mint-Ocy and Mint-Pyra). Statistical analysis was
performed by ANOVA and Tukey tests.
Taking into account that immunoconjugates are generally at least
five times more toxic than unconjugated toxins and that the treat-
ment protocol would include five administrations, the immuno-
toxin dose of each injection was fixed at 1/25 of the LD50 for
unconjugated toxins. Moreover, in order to obtain low variability
of tumour growth among mice, a rather high number of cells was
inoculated (10 per mouse). The treatment with either immunocon-
jugate, MintS or PBS was started at the same time as tumour
grafting and was repeated every other day for a total of five injec-
tions. Three days after the last injection, the mice were sacrificed
because ofevident weight loss, and both body and tumour weights
were determined. Table 2 data indicate that Mint-Ocy and
Mint-Pyra inhibit 57% and 47% of tumour growth respectively,
compared with mice treated with PBS. The inhibitory activity of
unconjugated Mint5 was only 7%, although the dose administered
was three and seven times higher then MintS conjugated to Ocy
and Pyra respectively. The necroscopic examination oftissues and
organs ofanimals treated with Mint-Ocy and Mint-Pyra immuno-
conjugates revealed no significant abnormalities, while micro-
scopic examination revealed a chronic inflammation, pigmentation
or margination ofthe cellular cytoplasm in the liver.
DISCUSSION
With the aim of obtaining selective toxic agents for cancer treat-
ment, many RIPs have been conjugated to carrier molecules
capable of delivering them to specific tumour cell populations.
Antibodies, usually monoclonals, are the obvious choice for
preparing conjugates, but hormones, growth factors and lectins
have also been used as carriers for cancer therapy (Lappi et al,
1991; Wawrzynczak et al, 1991). To date, ricin A has been the
most frequently used RIP in preparing immunoconjugates, but
more recently, several type 1 RIPs, namely gelonin, PAP saporin,
momordin, bryodin and barley RIP, have been used to explore
possible medical applications in cancer and autoimmune disease
therapy, treatment of graft vs host disease, parasite killing, etc.
(Barbieri et al, 1993). For in vivo therapy, the linkage between the
antigen-binding molecule and the toxin must be sufficiently stable
to remain intact until the immunotoxin reaches its target cells and
then the toxin must be released. A saporin-containing immuno-
toxin, prepared as described here, has been used previously in a
clinical trial for the treatment of refractory Hodgkin's disease and
proved to be very promising (Falini et al, 1992). Present results
indicate that Mint-Ocy and Mint-Pyra immunoconjugates exhibit
in vitro tumour cell recognition and inhibition ofcell proliferation
and protein synthesis. Moreover, the amount of conjugated RIPs
required to obtain 50% inhibition ranges from 1:100 to 1:10 000
the amount ofunconjugated toxins, indicating that, under different
experimental conditions, RIPs' action can be made highly specific
and potent. The preliminary in vivo study in tumour-grafted nude
mice treated with Mint-Ocy or Mint-Pyra indicates that immuno-
conjugates are able to control tumour progression efficiently even
when a high number of A431 tumour cells is inoculated (107 per
mouse compared with other studies in which A431 cells were
inoculated at 106 per mouse) (Baselga et al, 1993). The conditions
oftreatment forin vivo experiments were fixed in order to achieve
the maximum effect of immunoconjugates against a high number
ofgrafted tumour cells. The adopted dose regimen induced weight
loss in treated animals, probably owing to liver toxicity; thus,
further pharmacokinetic and toxicological studies will be neces-
sary to establish more controlled treatment protocols. Both in vitro
and in vivo results indicate that an anti-tumour activity can be
obtained by MintS/RIP conjugate. It is known that toxins and
murine antibodies induce an immune response in treated patients
(Frankel et al, 1995). Therefore, the identification of new RIPs
together with antibody 'humanization' procedures is particularly
important in enlarging the list ofimmunotoxins for clinical use.
Ocymoidine and pyramidatine were previously found to be
immunologically cross-reactive only with RIPs from some plants
belonging to the same Caryophyllaceae family, but not with RIPs
from otherplants (Bolognesi et al, 1995). Data from ourlaboratory
(not shown) indicate that, in spite of high N-terminal sequence
homology, Ocy and Pyra exhibit only 7.5% of reciprocal cross-
reactivity, suggesting their possible use in therapy with sequential
immunotoxin treatments. In addition to ocymoidine and pyramida-
tine, other RIPs are in preparation in our laboratory in order to
overcome the immunogenicity problems related to therapeutic
regimens requiring multiple administrations. Moreover, a human-
ized version of MintS antibody has been obtained recently in our
laboratory showing substantially the same properties of parental
MAb (Ferrer et al, 1997).
The EGFR overexpression in some tumour cells compared with
normal tissues has been indicated previously as an operational
marker fortumourtherapy with anti- EGFR monoclonal antibodies
(Ennis et al, 1991). Tosi et al (1995) show that MintS inhibits the
proliferation of tumour cell lines to the same extent despite the
difference in EGFR levels. The lack ofquantitative discrimination
ofthe levels ofEGFR on target cells is also reported in the present
paper with Mint-Ocy and Mint-Pyra immunoconjugates. In
contrast to our observation, some immunoconjugates with ricin
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toxin have been reported to be able to induce a stronger in vitro
inhibitory activity on those cell lines overexpressing EGFR (Masui
et al, 1989). Since, from our in vitro inhibitory experiments, the
IGR-OV-1 and MCF7 cell lines, which are expressing similar
EGFR levels, show different sensitivities to the toxic action of
immunoconjugates (Table 1), we believe that in vitro systems are
not fully predictive of the biological effects and toxicity of these
products in in vivo treatment. In the direction of specific targeting
oftoxins to EGFR oftumour cells, the generation ofimmunotoxins
directed against an oncogenic mutant ofEGFR has been published
recently (Lorimer et al, 1995). Mutated EGFR has been identified
on gliomas, breast and lung carcinomas, and monoclonal anti-
bodies directed against this mutant do not recognize the wild-type
receptor expressed on normal cells.
In general, thetoxicity dataobtained fromclinical trials withimmuno-
toxins induce caution fortheir systemic use (Frankel etal, 1995).
Possible therapeutic applications of Mint-Ocy and Mint-Pyra
immunoconjugates could include the locoregional treatment of
brain and bladder cancers. A recent communication reports
successful treatment of glioblastoma with immunotoxins directed
against the transferrin receptor (Laske et al, 1995). Taking into
consideration that glioblastoma cells overexpress EGFR, locore-
gional treatment with Mint-Ocy and Mint-Pyra immunoconju-
gates of residual tumour cells after surgery could also be
considered. In addition, for this particular application, the induc-
tion of immune response would be prevented by the haematoen-
cephalic barrier compartmentalization of immunoconjugates.
Since it is generally accepted that recombinant immunotoxins are
more stable and more efficient in tumour penetration compared
with chemical immunoconjugates (Friedman et al, 1993), the
genes coding for both ocymoidine and pyramidatine have been
isolated in Menarini Laboratories, and their expression in E. coli is
in progress either alone or in combination with MintS single-chain
Fv to obtain recombinant single-chain immunotoxins.
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